Selected major trials of dual CD19/CD22 CAR T-cell construct in B-ALL
| Reference . | Type of dual targeting . | Number of patients . | Median age (range), y . | CR + CRi (%) . | EFS/PFS . | Comments . |
|---|---|---|---|---|---|---|
| Wang et al 202054 | Coadministration | 51 | 27 (9-62) | 96 | Median PFS, 13.6 mo | -49% of responders relapsed-Lower efficacy for BM blasts ≥5% or CNS involvement |
| Liu et al 202155 | Coadministration (sequential) | 27 | 21 (1.6-55) | 85 | 18-mo EFS, 68% | -All patient had a prior allo-SCT-23% developed CAR T-cell–associated GVHD |
| Frey et al 202156 | Coadministration | 13 | 46 (28-72) | 85 | 10/11 responders in ongoing remission | 1 patient develop CAR-HLH |
| Annesley et al 202157 | Cotransduction | 23 | 12 (0.5-22) | 89 | — | Best persistence for CD22 CAR (compared with CD19 or dual CARs) |
| Cui et al 202124 | Bivalent (tandem) | 47 | 28 (6-56) | 100 | 12-mo LFS, 68% | 72% underwent subsequent allo-SCT with improved outcomes |
| Dai et al 202058 | Bivalent | 6 | 23.5 (17-44) | 100 | — | 3 of 6 patients relapsed by 12 mo |
| Spiegel et al 202159 | Bivalent (loop) | 17 | 47 (26-68) | 82 | Median PFS, 5.8 mo | |
| Cordoba et al 202161 | Bicistronic | 15 | 8 (4-16) | 86% | 12-mo EFS 32% | -Limited persistence-69% of responders relapsed |
| Reference . | Type of dual targeting . | Number of patients . | Median age (range), y . | CR + CRi (%) . | EFS/PFS . | Comments . |
|---|---|---|---|---|---|---|
| Wang et al 202054 | Coadministration | 51 | 27 (9-62) | 96 | Median PFS, 13.6 mo | -49% of responders relapsed-Lower efficacy for BM blasts ≥5% or CNS involvement |
| Liu et al 202155 | Coadministration (sequential) | 27 | 21 (1.6-55) | 85 | 18-mo EFS, 68% | -All patient had a prior allo-SCT-23% developed CAR T-cell–associated GVHD |
| Frey et al 202156 | Coadministration | 13 | 46 (28-72) | 85 | 10/11 responders in ongoing remission | 1 patient develop CAR-HLH |
| Annesley et al 202157 | Cotransduction | 23 | 12 (0.5-22) | 89 | — | Best persistence for CD22 CAR (compared with CD19 or dual CARs) |
| Cui et al 202124 | Bivalent (tandem) | 47 | 28 (6-56) | 100 | 12-mo LFS, 68% | 72% underwent subsequent allo-SCT with improved outcomes |
| Dai et al 202058 | Bivalent | 6 | 23.5 (17-44) | 100 | — | 3 of 6 patients relapsed by 12 mo |
| Spiegel et al 202159 | Bivalent (loop) | 17 | 47 (26-68) | 82 | Median PFS, 5.8 mo | |
| Cordoba et al 202161 | Bicistronic | 15 | 8 (4-16) | 86% | 12-mo EFS 32% | -Limited persistence-69% of responders relapsed |
BM, bone marrow; CNS, central nervous system.